Cleveland Biolabs (CBLI) Stock Price, Forecast & Analysis
USA - NASDAQ:CBLI -
CBLI Key Statistics, Chart & Performance
The current stock price of CBLI is 3.17 null. In the past month the price decreased by -10.96%. In the past year, price increased by 72.28%.
CBLI Latest News, Press Relases and Analysis
CBLI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.64 | 411.36B | ||
| AMGN | AMGEN INC | 15.37 | 181.00B | ||
| GILD | GILEAD SCIENCES INC | 15.31 | 155.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.03 | 111.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.48 | 73.85B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 890.53 | 59.53B | ||
| INSM | INSMED INC | N/A | 40.36B | ||
| NTRA | NATERA INC | N/A | 27.59B | ||
| BIIB | BIOGEN INC | 9.65 | 23.69B | ||
| INCY | INCYTE CORP | 16.41 | 20.57B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.33 | 20.68B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.61 | 14.35B |
Related stock screener links
About CBLI
Company Profile
Cytocom Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Fort Collins, Colorado and currently employs 2 full-time employees. The company went IPO on 2006-07-21. Cytocom, Inc., formerly Cleveland BioLabs, Inc., is a clinical-stage biopharmaceutical company. The firm is focused on developing small molecule immunotherapies, which targets autoimmune, inflammatory, infectious diseases and cancers. Its advanced immunomodulating multi-receptor system (AIMS) platform is a drug discovery and development platform, which is designed to restore immune homeostasis. Its immunomodulatory drugs are developed using AIMS platform, which adjusts immune responses to halt or slow disease progression. Its clinical-stage development programs are focused on treating Crohn's disease, fibromyalgia, multiple sclerosis and pancreatic cancer. The Company’s programs include CYTO-200 AIMS Program, CYTO-400 AIMS Program and CYTO-600 Program. The firm also has a platform of toll-like immune receptors (TLR4, TLR5 and TLR9), which address the conditions such as radiation sickness and cancer treatment side effects.
Company Info
Cleveland Biolabs
2537 Research Boulevard, Suite 201
Fort Collins COLORADO 14203 US
CEO: Christopher Zosh
Employees: 2
Phone: 18886138802.0
Cleveland Biolabs / CBLI FAQ
What does CBLI do?
Cytocom Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Fort Collins, Colorado and currently employs 2 full-time employees. The company went IPO on 2006-07-21. Cytocom, Inc., formerly Cleveland BioLabs, Inc., is a clinical-stage biopharmaceutical company. The firm is focused on developing small molecule immunotherapies, which targets autoimmune, inflammatory, infectious diseases and cancers. Its advanced immunomodulating multi-receptor system (AIMS) platform is a drug discovery and development platform, which is designed to restore immune homeostasis. Its immunomodulatory drugs are developed using AIMS platform, which adjusts immune responses to halt or slow disease progression. Its clinical-stage development programs are focused on treating Crohn's disease, fibromyalgia, multiple sclerosis and pancreatic cancer. The Company’s programs include CYTO-200 AIMS Program, CYTO-400 AIMS Program and CYTO-600 Program. The firm also has a platform of toll-like immune receptors (TLR4, TLR5 and TLR9), which address the conditions such as radiation sickness and cancer treatment side effects.
Can you provide the latest stock price for Cleveland Biolabs?
The current stock price of CBLI is 3.17 null. The price decreased by -7.31% in the last trading session.
What is the dividend status of Cleveland Biolabs?
CBLI does not pay a dividend.
How is the ChartMill rating for Cleveland Biolabs?
CBLI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for Cleveland Biolabs?
Cleveland Biolabs (CBLI) has a market capitalization of 49.07M null. This makes CBLI a Nano Cap stock.
CBLI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CBLI. When comparing the yearly performance of all stocks, CBLI turns out to be only a medium performer in the overall market: it outperformed 54.61% of all stocks.
CBLI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CBLI. CBLI has a great financial health rating, but its profitability evaluates not so good.
CBLI Financial Highlights
Over the last trailing twelve months CBLI reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS decreased by -5.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -6049.77% | ||
| ROA | -19.07% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |